Rigel Pharmaceuticals Inc
NASDAQ:RIGL
Rigel Pharmaceuticals Inc
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company is headquartered in South San Francisco, California and currently employs 165 full-time employees. The company went IPO on 2000-11-29. The firm is engaged in discovering, developing and providing small molecule drugs that improve the lives of patients with hematologic disorders, cancer and rare immune diseases. The firm's research focuses on signaling pathways that are critical to disease mechanisms. The firm's product, TAVALISSE (fostamatinib disodium hexahydrate) tablets, the spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia (ITP). The Company’s product is also commercially available in Europe, the United Kingdom (UK) (TAVLESSE) and Canada (TAVALISSE) for the treatment of chronic ITP in adult patients. Its clinical programs include its interleukin receptor-associated kinase (IRAK) inhibitor program and a receptor-interacting serine/threonine-protein kinase (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company (Lilly).
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company is headquartered in South San Francisco, California and currently employs 165 full-time employees. The company went IPO on 2000-11-29. The firm is engaged in discovering, developing and providing small molecule drugs that improve the lives of patients with hematologic disorders, cancer and rare immune diseases. The firm's research focuses on signaling pathways that are critical to disease mechanisms. The firm's product, TAVALISSE (fostamatinib disodium hexahydrate) tablets, the spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia (ITP). The Company’s product is also commercially available in Europe, the United Kingdom (UK) (TAVLESSE) and Canada (TAVALISSE) for the treatment of chronic ITP in adult patients. Its clinical programs include its interleukin receptor-associated kinase (IRAK) inhibitor program and a receptor-interacting serine/threonine-protein kinase (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company (Lilly).
Record Revenue: Rigel reported total Q3 2025 revenue of $69.5 million, with net product sales of $64.1 million, up 65% year-over-year and a new record.
Guidance Raised: The company increased its 2025 revenue outlook to $285–290 million (up from $270–280 million) and net product sales guidance to $225–230 million.
Strong Net Income: Q3 net income reached $27.9 million, more than double the $12.4 million from the prior year.
Cash Balance Up: Cash, cash equivalents, and short-term investments grew to $137.1 million from $77.3 million at the end of 2024.
Commercial Momentum: All three commercial products (TAVALISSE, GAVRETO, REZLIDHIA) posted strong sales growth, driven by higher demand and improved patient affordability.
Pipeline Progress: R289 Phase Ib dose escalation completed enrollment, with updated data to be presented at ASH in December; dose expansion phase has begun.
Strategic Collaborations: Rigel expanded development of olutasidenib with new studies and partnerships, including MD Anderson, CONNECT, and MyeloMATCH.
